FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2893863004> ?p ?o ?g. }

• W2893863004 endingPage "275" @default.
• W2893863004 startingPage "238" @default.
• W2893863004 abstract "Abstract Objective – To briefly describe the history of and available data on anti‐calcitonin gene‐related peptide (CGRP) therapies for headache. Background – CGRP was proposed as a target for primary headache therapies. Translational research involved moving from delineating the relationships between CGRP and primary headaches and the clinical development of anti‐CGRP treatments. The first anti‐CGRP treatment, an intravenous CGRP‐receptor antagonist or gepant, olcegepant, was described as effective in terminating migraines in humans in 2004. Methods – The author briefly reviews some of the pathophysiology and translational research that led to the development of the gepants initially and then subsequently to the anti‐CGRP and anti‐CGRP receptor monoclonal antibodies. All accessible randomized controlled trials, abstracts, platform presentations, and press releases on the monoclonal antibody trials are summarized. The trajectory from bench research to the approval of the first anti‐CGRP receptor monoclonal antibody for clinical use in migraine prevention, erenumab, is discussed, as well as potential clinical uses of the anti‐CGRP treatments. Results – The US Food and Drug Administration (FDA) approved erenumab, an anti‐CGRP receptor monoclonal antibody, for prevention of migraine May 17, 2018. At the time of this writing (May 2018), 2 other anti‐CGRP monoclonal antibodies have been submitted to the FDA for the indication of prevention of migraine, galcanezumab and fremanezumab. Galcanezumab has reportedly shown effectiveness in preventing episodic cluster headache as well, although has not yet been submitted to the FDA for this indication. Eptinezumab will likely be submitted to the FDA for prevention of migraine later in 2018. Two gepants, ubrogepant and rimegepant, have completed positive pivotal trials for acute treatment of migraine, but have not yet been submitted to the FDA for this indication. Conclusions – The development of anti‐CGRP therapies opens a new era in the acute and preventive treatment of primary headache disorders." @default.
• W2893863004 created "2018-10-05" @default.
• W2893863004 creator A5064341657 @default.
• W2893863004 date "2018-09-22" @default.
• W2893863004 modified "2023-10-18" @default.
• W2893863004 title "History and Review of anti‐Calcitonin Gene‐Related Peptide (CGRP) Therapies: From Translational Research to Treatment" @default.
• W2893863004 cites W1877892144 @default.
• W2893863004 cites W1975937091 @default.
• W2893863004 cites W1983283512 @default.
• W2893863004 cites W2004916007 @default.
• W2893863004 cites W2009688249 @default.
• W2893863004 cites W2014690013 @default.
• W2893863004 cites W2021813766 @default.
• W2893863004 cites W2028860345 @default.
• W2893863004 cites W2029253166 @default.
• W2893863004 cites W2037206898 @default.
• W2893863004 cites W2038078887 @default.
• W2893863004 cites W2038399206 @default.
• W2893863004 cites W2039523986 @default.
• W2893863004 cites W2048132386 @default.
• W2893863004 cites W2055541495 @default.
• W2893863004 cites W2061453158 @default.
• W2893863004 cites W2062955354 @default.
• W2893863004 cites W2063116792 @default.
• W2893863004 cites W2065782606 @default.
• W2893863004 cites W2066998820 @default.
• W2893863004 cites W2076160539 @default.
• W2893863004 cites W2080865467 @default.
• W2893863004 cites W2083276084 @default.
• W2893863004 cites W2085206766 @default.
• W2893863004 cites W2085595272 @default.
• W2893863004 cites W2086228377 @default.
• W2893863004 cites W2087994192 @default.
• W2893863004 cites W2091306804 @default.
• W2893863004 cites W2110938100 @default.
• W2893863004 cites W2116458765 @default.
• W2893863004 cites W2117166151 @default.
• W2893863004 cites W2135858080 @default.
• W2893863004 cites W2137787323 @default.
• W2893863004 cites W2137924809 @default.
• W2893863004 cites W2138814983 @default.
• W2893863004 cites W2145294984 @default.
• W2893863004 cites W2148445312 @default.
• W2893863004 cites W2153751480 @default.
• W2893863004 cites W2155781531 @default.
• W2893863004 cites W2157733244 @default.
• W2893863004 cites W2162942726 @default.
• W2893863004 cites W2166430034 @default.
• W2893863004 cites W2268603990 @default.
• W2893863004 cites W2283260670 @default.
• W2893863004 cites W2309413820 @default.
• W2893863004 cites W2317957978 @default.
• W2893863004 cites W2410854297 @default.
• W2893863004 cites W2412579902 @default.
• W2893863004 cites W2466122216 @default.
• W2893863004 cites W2608751463 @default.
• W2893863004 cites W2623864543 @default.
• W2893863004 cites W2748627085 @default.
• W2893863004 cites W2766819558 @default.
• W2893863004 cites W2768357559 @default.
• W2893863004 cites W2770965214 @default.
• W2893863004 cites W2790167276 @default.
• W2893863004 cites W2792811290 @default.
• W2893863004 cites W2801085490 @default.
• W2893863004 cites W2802956375 @default.
• W2893863004 cites W2803715733 @default.
• W2893863004 cites W2955580540 @default.
• W2893863004 doi "https://doi.org/10.1111/head.13379" @default.
• W2893863004 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30242830" @default.
• W2893863004 hasPublicationYear "2018" @default.
• W2893863004 type Work @default.
• W2893863004 sameAs 2893863004 @default.
• W2893863004 citedByCount "116" @default.
• W2893863004 countsByYear W28938630042018 @default.
• W2893863004 countsByYear W28938630042019 @default.
• W2893863004 countsByYear W28938630042020 @default.
• W2893863004 countsByYear W28938630042021 @default.
• W2893863004 countsByYear W28938630042022 @default.
• W2893863004 countsByYear W28938630042023 @default.
• W2893863004 crossrefType "journal-article" @default.
• W2893863004 hasAuthorship W2893863004A5064341657 @default.
• W2893863004 hasConcept C118303440 @default.
• W2893863004 hasConcept C126322002 @default.
• W2893863004 hasConcept C141071460 @default.
• W2893863004 hasConcept C159654299 @default.
• W2893863004 hasConcept C163170386 @default.
• W2893863004 hasConcept C163864487 @default.
• W2893863004 hasConcept C170493617 @default.
• W2893863004 hasConcept C203014093 @default.
• W2893863004 hasConcept C2777942821 @default.
• W2893863004 hasConcept C2778541695 @default.
• W2893863004 hasConcept C2779627488 @default.
• W2893863004 hasConcept C2780966972 @default.
• W2893863004 hasConcept C535046627 @default.
• W2893863004 hasConcept C542903549 @default.
• W2893863004 hasConcept C71924100 @default.
• W2893863004 hasConcept C98274493 @default.
• W2893863004 hasConceptScore W2893863004C118303440 @default.

• next